Success Metrics

Clinical Success Rate
87.0%

Based on 20 completed trials

Completion Rate
87%(20/23)
Active Trials
0(0%)
Results Posted
30%(6 trials)
Terminated
3(12%)

Phase Distribution

Ph phase_2
3
12%
Ph phase_3
10
40%
Ph phase_4
10
40%
Ph not_applicable
1
4%
Ph phase_1
1
4%

Phase Distribution

1

Early Stage

3

Mid Stage

20

Late Stage

Phase Distribution25 total trials
Phase 1Safety & dosage
1(4.0%)
Phase 2Efficacy & side effects
3(12.0%)
Phase 3Large-scale testing
10(40.0%)
Phase 4Post-market surveillance
10(40.0%)
N/ANon-phased studies
1(4.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.0%

20 of 23 finished

Non-Completion Rate

13.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

25

all time

Status Distribution
Completed(20)
Terminated(3)
Other(2)

Detailed Status

Completed20
Terminated3
unknown2

Development Timeline

Analytics

Development Status

Total Trials
25
Active
0
Success Rate
87.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (4.0%)
Phase 23 (12.0%)
Phase 310 (40.0%)
Phase 410 (40.0%)
N/A1 (4.0%)

Trials by Status

terminated312%
unknown28%
completed2080%

Recent Activity

Clinical Trials (25)

Showing 20 of 25 trialsScroll for more
NCT00836823Phase 4

Evaluation of Symptom-specific Goal Achievement

Completed
NCT00696761Phase 4

The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients

Completed
NCT00103402Phase 3

Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Completed
NCT01834729Phase 2

Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions

Completed
NCT00893113Phase 3

An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms

Completed
NCT02977832Not Applicable

Clinical Results of Odyliresin (Iresine Celosia) in Symptomatic Benign Prostatic Hyperplasia

Completed
NCT00576823Phase 3

Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology

Completed
NCT00549939Phase 3

Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction

Completed
NCT02266537Phase 1

Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers

Completed
NCT00451061Phase 4

The Efficacy of Alpha-blockers for Expulsion of Distal Ureteral Stones

Unknown
NCT00713739Phase 3

Alfuzosin for Medical Expulsion Therapy of Ureteral Stones

Unknown
NCT00688948Phase 2

Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS)

Terminated
NCT00280605Phase 4

ALF-ONE : ALFuzosin ONcE Daily

Completed
NCT00399464Phase 3

Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia

Completed
NCT00486785Phase 4

SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin

Completed
NCT00401661Phase 4

Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin

Completed
NCT00336921Phase 2

Alfuzosin for Treating Acute Urinary Retention

Completed
NCT00290030Phase 3

ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH

Completed
NCT00575913Phase 4

Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study

Completed
NCT00637715Phase 4

Once Daily Given Alfuzosin in the Treatment of BPH

Completed

Drug Details

Intervention Type
DRUG
Total Trials
25